India's homegrown Covaxin jab is "highly efficacious" against symptomatic Covid-19, a study by the medical journal Lancet has revealed.
The vaccine, which is developed by the Hyderabad-based Bharat Biotech, is 77.2 per cent effective against Covid-19 and 70.8 per cent effective against all variants of the SARS-CoV-2 virus.
The efficacy rate was confirmed through the evaluation of 130 confirmed cases, with 24 observed in the vaccine group, while 106 were in the placebo group.
According to the Phase 3 data published in the study, Covaxin was found to be 65.2 per cent effective against the Delta variant, 93.4 per cent effective against severe symptomatic Covid and 63.6 per cent effective against asymptomatic Covid.
Meanwhile, the World Health Organisation (WHO) on Twitter said Covaxin is “extremely suitable for low- and middle-income countries due to easy storage requirements".
As a result of that and its high efficacy rates, WHO recently added Covaxin to its approved Covid-19 vaccine list.
The Lancet study noted that further research is required to discover the vaccine's long-term safety and effectiveness, as well as its ability to protect against severe illness, hospitalisation and death.
The way it hugs the road the faster you go, the horsepower, the styling… all of it combined makes the 488 Pista an exciting car to drive
You need to know them because they are, in fact, commonly used in English, while remaining recognisably foreign
Gadgets and watches are not just your tech assistants and timekeepers anymore
From 'Big T' to 'Little T', recognising the diversity of experiences that shape mental well-being is paramount
The Polish player is through to the semifinals of the Dubai Duty Free Tennis Championships for the second straight year
Here are some tips on how to feel more included in their world